Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
terguride
- Development stage
- Unknown
- Lead developer
- ErgoNex Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Terguride is a synthetic ergoline derivative and small molecule drug that acts as a partial agonist at dopamine D2 receptor and an antagonist at serotonin 5-HT2A receptor and serotonin 5-HT2B receptor. It also exhibits activity at other serotonergic, dopaminergic, and adrenergic receptors. Terguride inhibits pituitary prolactin secretion by stimulating dopamine D2 receptors in the pituitary gland, making it effective for the treatment of hyperprolactinemia. It has also been investigated for use in pulmonary arterial hypertension (PAH), systemic sclerosis, Parkinson's disease, schizophrenia, fibromyalgia, and fibrosis. The drug was originally developed by Bayer HealthCare Pharmaceuticals and has received full marketing authorization in Japan for hyperprolactinemia; development for other indications such as PAH has been discontinued or terminated outside Japan[1][3][6][7].
- Brand names
- Dironyl
- Other names
- tergurideDironyl
02
Targets
HTR2C (5-hydroxytryptamine 2C receptor)DRD2 (Dopamine D2 Receptor)HTR2A (Serotonin receptor 5-HT2A)HTR2B (5-Hydroxytryptamine Receptor 2B)
Beyond the preview
Go deeper on terguride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on terguride.